Pharmacogenomic Determinants of the Cardiovascular Effects of Dalcetrapib
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Background—: Dalcetrapib did not improve clinical outcomes, despite increasing high-density lipoprotein cholesterol by 30%. These results differ from other evidence supporting high-density lipoprotein as a therapeutic target. Responses to dalcetrapib may vary according to patients’ genetic profile. Methods and Results—: We conducted a pharmacogenomic evaluation using a genome-wide approach in the dal-OUTCOMES study (discovery cohort, n=5749) and a targeted genotyping panel in the dal-PLAQUE-2 imaging trial (support cohort, n=386). The primary endpoint for the discovery cohort was a composite of cardiovascular events. The change from baseline in carotid intima-media thickness on ultrasonography at 6 and 12 months was evaluated as supporting evidence. A single-nucleotide polymorphism was found to be associated with cardiovascular events in the dalcetrapib arm, identifying the ADCY9 gene on chromosome 16 (rs1967309; P =2.41×10 –8 ), with 8 polymorphisms providing P <10 –6 in this gene. Considering patients with genotype AA at rs1967309, there was a 39% reduction in the composite cardiovascular endpoint with dalcetrapib compared with placebo (hazard ratio, 0.61; 95% confidence interval, 0.41–0.92). In patients with genotype GG, there was a 27% increase in events with dalcetrapib versus placebo. Ten single-nucleotide polymorphism in the ADCY9 gene, the majority in linkage disequilibrium with rs1967309, were associated with the effect of dalcetrapib on intima-media thickness ( P <0.05). Marker rs2238448 in ADCY9 , in linkage disequilibrium with rs1967309 ( r 2 =0.8), was associated with both the effects of dalcetrapib on intima-media thickness in dal-PLAQUE-2 ( P =0.009) and events in dal-OUTCOMES ( P =8.88×10 –8 ; hazard ratio, 0.67; 95% confidence interval, 0.58–0.78). Conclusions—: The effects of dalcetrapib on atherosclerotic outcomes are determined by correlated polymorphisms in the ADCY9 gene. Clinical Trial Information—: URL: http://www.clinicaltrials.gov . Unique identifiers: NCT00658515 and NCT01059682
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139 · cited 1×
“ing HDL-cholesterol levels by ≈70% although elevations of aldosterone levels and blood pressure observed in some patients may have contributed to the negative findings.(3) Dalcetrapib is another cholesteryl ester transfer protein inhibitor that raises HDL-cholesterol levels by ≈30%, without effects on circulating neur…”
BackgroundSelf-citationNiacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Effects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022 · cited 3×
“Dalcetrapib failed to improve clinical outcomes among the 15 871 patients of the dal-OUTCOMES study, with no subgroups defined by baseline clinical or biochemical characteristics appearing to benefit from therapy.(4) These results are at odds with those from epidemiological, clinical, rare family genetic, animal model…”
MethodResultInfluentialSelf-citationA linear complexity phasing method for thousands of genomes
Delaneau, O., Marchini, J., & Zagury, J.-F. (2012) · Nature Methods · doi:10.1038/nmeth.1785 · Cited by 1,850 · cited 1×
“Phasing was performed using the shapeit2 algorithm (version 2r790).(11) A total of 28 846 501 genetic variants with imputation probability of ≥0.”
MethodGao, X., Starmer, J., & Martin, E. R. (2008) · Genetic Epidemiology · doi:10.1002/gepi.20310 · Cited by 849
HPS2-THRIVE Collaborative Group, Haynes, R., Jiang, L., Hopewell, J. C., Li, J., Chen, F., Parish, S., Landray, M. J., Collins, R., Armitage, J., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht055 · Cited by 676
Berndt, S. I., Gustafsson, S., Mägi, R., Ganna, A., Wheeler, E., Feitosa, M. F., Justice, A. E., Monda, K. L., Croteau-Chonka, D. C., Day, F. R., et al. (2013) · Nature Genetics · doi:10.1038/ng.2606 · Cited by 646 · cited 1×
“Recently, another ADCY9 gene polymorphism was shown to be associated with bodymass index and clinical classes of obesity.(16) In our study, polymorphisms in the ADCY9 gene influenced responses to dalcetrapib in terms of body mass index, weight, plasma LDL-cholesterol, LDL/HDL cholesterol ratio, and triglycerides (Figu…”
BackgroundBesler, C., Heinrich, K., Rohrer, L., Doerries, C., Riwanto, M., Shih, D. M., Chroni, A., Yonekawa, K., Stein, S., Schaefer, N., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci42946 · Cited by 535 · cited 1×
“In contrast, HDL has been shown to lose some of its beneficial properties to varying degrees in patients with coronary artery disease.(7) We hypothesized that responses to dalcetrapib vary among patients, based on their genetic profile.”
ResultNovel Regulatory Properties of Human Type 9 Adenylate Cyclase
Cumbay, M. G., & Watts, V. J. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.065748 · Cited by 76 · cited 2×
“ADCY9 is the ninth, least well characterized and widely distributed isoform of adenylate cyclase, the membranebound enzyme responsible for the formation of cAMP from ATP.14 Adenylate cyclase transducts various extracellular stimuli into intracellular signaling and is regulated by different factors, including G-protein…”
Background
Cited by
Dysfunctional HDL and atherosclerotic cardiovascular disease
Rosenson, R. S., Brewer, H. B., Ansell, B. J., Barter, P., Chapman, M. J., Heinecke, J. W., Kontush, A., Tall, A. R., & Webb, N. R. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.124 · Cited by 822
A robust and efficient method for Mendelian randomization with hundreds of genetic variants
Burgess, S., Foley, C. N., Allara, E., Staley, J. R., & Howson, J. M. M. (2020) · Nature Communications · doi:10.1038/s41467-019-14156-4 · Cited by 681
Roden, D. M., McLeod, H. L., Relling, M. V., Williams, M. S., Mensah, G. A., Peterson, J. F., & Van Driest, S. L. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31276-0 · Cited by 427
Dessauer, C. W., Watts, V. J., Ostrom, R. S., Conti, M., Dove, S., & Seifert, R. (2017) · Pharmacological Reviews · doi:10.1124/pr.116.013078 · Cited by 201
Cholesteryl Ester Transfer Protein Inhibition for Preventing Cardiovascular Events
Armitage, J., Holmes, M. V., & Preiss, D. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.10.072 · Cited by 140
“A speculative, subgroup post hoc pharmacogenomics analysis showed that the presence of SNPs in the ADCY9 gene on chromosome 16 were associated with favorable effects on cardiovascular events and carotid intima-media thickness progression with dalcetrapib (26).”
Background
Metadata
- Authors
- Tardif, J.-C., Rhéaume, E., Lemieux Perreault, L.-P., Grégoire, J. C., Feroz Zada, Y., Asselin, G., Provost, S., Barhdadi, A., Rhainds, D., L’Allier, P. L., Ibrahim, R., Upmanyu, R., Niesor, E. J., Benghozi, R., Suchankova, G., Laghrissi-Thode, F., Guertin, M.-C., Olsson, A. G., Mongrain, I., Schwartz, G. G., & Dubé, M.-P.
- Venue
- Circulation: Cardiovascular Genetics
- Published
- 2015-04
- Volume
- 8
- Issue
- 2
- Pages
- 372-382
- ISSN
- 1942-325X (ISSN-L)
- 1942-3268
- OpenAlex
- W2099697702
- Cited by
- 185
- References
- 9
- FWCI
- 27.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacogenomic Determinants of the Cardiovascular Effects of Dalcetrapib. https://app.cochat.ai/papers/10.1161/circgenetics.114.000663
- The paper
- Tardif, J.-C., Rhéaume, E., Lemieux Perreault, L.-P., Grégoire, J. C., Feroz Zada, Y., Asselin, G., Provost, S., Barhdadi, A., Rhainds, D., L’Allier, P. L., Ibrahim, R., Upmanyu, R., Niesor, E. J., Benghozi, R., Suchankova, G., Laghrissi-Thode, F., Guertin, M.-C., Olsson, A. G., Mongrain, I., . . . Dubé, M.-P. (2015). Pharmacogenomic Determinants of the Cardiovascular Effects of Dalcetrapib. Circulation: Cardiovascular Genetics. https://doi.org/10.1161/circgenetics.114.000663
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.